Use of autologous ADSCs for ovarian rejuvenation

By Dr Yvonne Holt

22 May 2023

Treating patients with poor ovarian responsiveness remains challenging and pregnancy rate following invitro fertilisation are low. Advances in adult stem cell research and their clinical application prompted interest in their use in assisted reproduction.  

Next Biosciences teamed up with BioART Fertility Centre in this first double-blind, randomised, placebo-controlled clinical study using autologous human stromal vascular fraction (SVF) containing adipose-derived stem cells (ADSCs) for ovarian rejuvenation.

Adipose-Derived Stem Cells are a type of stem cell that can be found in adipose tissue or fat. ADSCs have the ability to self-renew and differentiate into a variety of different cell types, including cells that can support the growth and development of ovarian follicles.

We found that when ADSCs are injected into the ovaries, they release a variety of growth factors and other signalling molecules that have shown promising outcomes for increased ovarian reserve and improved quality of eggs. This can lead to an increase in the number of eggs available for fertilisation, which can improve a woman's chances of conceiving.

ADSC therapy is a promising new treatment option for women with diminished ovarian reserve. Although this remains experimental, the current study provides further support for the safety of this approach and presents encouraging results as to its efficacy in assisted reproduction.

Next Biosciences remains at the forefront of scientific discovery and is committed to investigating how we can positively impact people’s health through cutting-edge science.

Explore the study here: Use of autologous adipose derived mesenchymal stem cells